Marc Engelhardt

7PUBLICATIONS
13CO-AUTHORS
Environmental epidemiologyPharmacogenomicsMolecular targetsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 23, 2026
No clinically relevant QTc prolongation with ceftibuten or ledaborbactam etzadroxil: concentration-QTc analyses from two phase I studies.

|Sep 28, 2026
Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment.

|Apr 20, 2026
Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults.

|Jun 24, 2025
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

Andrew F Shorr, Mark E Jones, Silke Friedmann

|Oct 07, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.

Matthias Holdhoff, Xiaobu Ye, Roy E Strowd

|Apr 16, 2024
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

Andrea Necchi, Rodryg Ramlau, Alejandro Falcón González

Pageof 2

Frequent Collaborators

4 joint publications

Kamal Hamed

3 joint publications

Paul C McGovern

3 joint publications

Karine Litherland

2 joint publications

Carlos Fernando de Oliveira